World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
78
Citations
31121
World Ranking
17847
National Ranking
275

Overview

Jerome B. Zeldis is affiliated with Bristol-Myers Squibb (Switzerland) in Switzerland and focuses their research primarily within the field of Medicine. Their work spans several subfields including Oncology, Infectious Diseases, Immunology, Molecular Biology, and Radiology, Nuclear Medicine and Imaging.

The scientist has contributed to multiple aspects of biomedical research, with main topics that encompass:

  • CAR-T cell therapy research
  • Monoclonal and Polyclonal Antibodies Research
  • SARS-CoV-2 and COVID-19 Research
  • PARP inhibition in cancer therapy
  • Viral Infections and Outbreaks Research
  • Parasitic Diseases Research and Treatment
  • Parasite Biology and Host Interactions

Their publications demonstrate a focus on immunotherapy, viral disease research, and parasitic disease treatment. Recent papers include:

  • The IMPDH inhibitor merimepodib provided in combination with the adenosine analogue remdesivir reduces SARS-CoV-2 replication to undetectable levels in vitro, 2020, F1000Research
  • Filarial nematode phenotypic screening cascade to identify compounds with anti-parasitic activity for drug discovery optimization, 2022, International Journal for Parasitology Drugs and Drug Resistance
  • AIM™ platform: A new immunotherapy approach for viral diseases, 2022, Frontiers in Medicine
  • Abstract 2188: Generation and characterization of human placental-derived CD19 CAR-T cells using viral vectors, 2020, Cancer Research
  • Prior Antigen Exposure Enhances the T Cell Response to Bispecific T Cell Engager Therapy, 2023, Transplantation and Cellular Therapy

The scientist frequently collaborates with peers including Ruipeng Wang, Mathias Oelke, Keshanti Tidwell, Adam R. Parks, and Shweta Jain.

Jerome B. Zeldis has published in a variety of journals, illustrating a multidisciplinary approach, with frequent publication venues such as:

  • F1000Research
  • International Journal for Parasitology Drugs and Drug Resistance
  • Frontiers in Medicine
  • Cancer Research
  • Transplantation and Cellular Therapy

Best Publications

  • Antitumor activity of thalidomide in refractory multiple myeloma.

    S Singhal;J Mehta;R Desikan;D Ayers

  • Lenalidomide plus Dexamethasone for Relapsed or Refractory Multiple Myeloma

    Meletios Dimopoulos;Andrew Spencer;Michael Attal;H. Miles Prince

  • Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion.

    Alan List;Gordon Dewald;John Bennett;Aristotle Giagounidis

  • Lenalidomide plus Dexamethasone for Relapsed Multiple Myeloma in North America

    Donna M. Weber;Christine Chen;Ruben Niesvizky;Michael Wang

  • Efficacy of lenalidomide in myelodysplastic syndromes.

    Alan List;Sandy Kurtin;Denise J. Roe;Andrew Buresh

  • Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma

    Paul G. Richardson;Robert L. Schlossman;Robert L. Schlossman;Edie Weller;Edie Weller;Teru Hideshima;Teru Hideshima

  • Extended survival in advanced and refractory multiple myeloma after single-agent thalidomide: identification of prognostic factors in a phase 2 study of 169 patients.

    Bart Barlogie;Raman Desikan;Raman Desikan;Paul Eddlemon;Paul Eddlemon;Trey Spencer;Trey Spencer

  • A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma

    Paul G. Richardson;Emily Blood;Constantine S. Mitsiades;Sundar Jagannath

  • Phase 2 study of lenalidomide in transfusion-dependent, low-risk, and intermediate-1–risk myelodysplastic syndromes with karyotypes other than deletion 5q

    Azra Raza;James A. Reeves;Eric J. Feldman;Gordon W. Dewald

  • Long-term follow-up on overall survival from the MM-009 and MM-010 phase III trials of lenalidomide plus dexamethasone in patients with relapsed or refractory multiple myeloma.

    M A Dimopoulos;C Chen;A Spencer;R Niesvizky

  • Lenalidomide monotherapy in relapsed or refractory aggressive non-Hodgkin's lymphoma

    Peter H. Wiernik;Izidore S. Lossos;Joseph M. Tuscano;Glen Justice

  • Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of Thalidomide Plus Dexamethasone Compared With Dexamethasone As Initial Therapy for Newly Diagnosed Multiple Myeloma

    S. Vincent Rajkumar;Laura Rosiñol;Mohamad Hussein;John Catalano

  • A phase 2 trial of combination low-dose thalidomide and prednisone for the treatment of myelofibrosis with myeloid metaplasia

    Ruben A. Mesa;David P. Steensma;David P. Steensma;Animesh Pardanani;Animesh Pardanani;Chin Yang Li;Chin Yang Li

  • Melphalan, Prednisone, and Lenalidomide Treatment for Newly Diagnosed Myeloma: A Report From the GIMEMA—Italian Multiple Myeloma Network

    Antonio Palumbo;Patrizia Falco;Paolo Corradini;Antonietta Falcone

  • Lenalidomide Oral Monotherapy Produces Durable Responses in Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma

    Thomas E. Witzig;Peter H. Wiernik;Timothy Moore;Craig Reeder

  • An open-label pilot study of low-dose thalidomide in chronically active, steroid-dependent Crohn's disease.

    Eric A. Vasiliauskas;Lori Y. Kam;Maria T. Abreu-Martin;Philip V. Hassard

  • Lenalidomide in combination with rituximab for patients with relapsed or refractory mantle-cell lymphoma: a phase 1/2 clinical trial

    Michael Wang;Luis Fayad;Nicolaus A Wagner-Bartak;Liang Zhang

  • Lenalidomide oral monotherapy produces a high response rate in patients with relapsed or refractory mantle cell lymphoma.

    Thomas M. Habermann;Izidore S. Lossos;Glen Justice;Julie M. Vose

  • Pharmacokinetics of lenalidomide in subjects with various degrees of renal impairment and in subjects on hemodialysis.

    Nianhang Chen;Henry Lau;Linghui Kong;Gondi Kumar

  • Lenalidomide therapy in myelofibrosis with myeloid metaplasia.

    Ayalew Tefferi;Jorge E Cortes;Jorge E Cortes;Jorge E Cortes;Srdan Verstovsek;Srdan Verstovsek;Srdan Verstovsek;Ruben A. Mesa;Ruben A. Mesa;Ruben A. Mesa

Frequent Co-Authors

Meletios A. Dimopoulos
Meletios A. Dimopoulos National and Kapodistrian University of Athens
David C. Seldin
David C. Seldin Boston University
Edward A. Stadtmauer
Edward A. Stadtmauer University of Pennsylvania
Julie M. Vose
Julie M. Vose University of Nebraska Medical Center
Gilla Kaplan
Gilla Kaplan Bill & Melinda Gates Foundation
Andrew Spencer
Andrew Spencer Monash University
Rob Knight
Rob Knight University of California, San Diego
Maurizio Zangari
Maurizio Zangari University of Arkansas for Medical Sciences

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

If you’re interested in studying medicine in the USA, you may also want to explore related online degrees that can open up diverse career paths in healthcare. Cheapest online healthcare administration degree programs offer a flexible way to enter healthcare leadership roles without the high cost or need to relocate.

For those seeking more advanced opportunities, the cheapest online master degree in healthcare administration can boost your credentials and prepare you for upper management positions.

If you’re considering advanced clinical practice, exploring most affordable online dnp programs can be a strategic step in becoming a Doctor of Nursing Practice, allowing for greater patient impact and leadership potential.

Pharmacy is another high-demand field. Pursuing a pharmacy degree online is becoming increasingly accessible and can prepare you for vital roles in medication management, research, and patient care.

These online pathways provide flexibility, affordability, and a strong foundation for those interested in health and medicine outside of the traditional MD track.

Best Scientists Citing Jerome B. Zeldis

Trending Scientists